Skip to main content

Effective dose from radiopharmaceuticals

This is a preview of subscription content, access via your institution.

References

  1. Johansson L, Mattsson S, Nosslin B, Leide-Svegborn S. Effective dose from radiopharmaceuticals. Eur J Nucl Med 1992; 19:933–938

    Google Scholar 

  2. Newsletter. J Nucl Med 1990; 31:13A–19A

  3. Hall P, Boice JD, Berg GB, Bjelkengren G, Ericson U, Hallquist A, Lidberg M, Lundell G, Mattison A, Tennvall J, Wiklund K, Holm L. Leukaemia incidence after 1131 exposure. Lancet 1992; 340:1–4

    Google Scholar 

References

  1. Macleod MA, Kemp PM. Eur J Nucl Med 1993; 20:448–449

    Google Scholar 

  2. Johansson L, Mattsson S, Nosslin B, Leide-Svegborn S. Effective dose from radiopharmaceuticals. Eur J Nucl Med 1992; 19:933–938.

    Google Scholar 

  3. ICRP Publication 26. Recommendations of the ICRP. Oxford: Pergamon, 1977.

  4. ICRP Publication 60. 1990 recommendations of the International Commission on Radiological Protection. Oxford: Pergamon, 1991.

  5. Hall P, Boice JD Jr, Berg G, et al. Leukaemia incidence after iodine-131 exposure. Lancet 1992; 340:1–4.

    Google Scholar 

  6. ICRP Publication 53. Radiation dose to patients from radiopharmaceuticals. Oxford: Pergamon, 1988.

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Macleod, M.A., Kemp, P.M., Johansson, L. et al. Effective dose from radiopharmaceuticals. Eur J Nucl Med 20, 448 (1993). https://doi.org/10.1007/BF00209006

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00209006

Keywords

  • Public Health
  • Nuclear Medicine
  • Effective Dose